RTK mutations and human syndromes: when good receptors turn bad
暂无分享,去创建一个
Donoghue | D. Donoghue | S. Robertson | J. Tynan | Robertson | Tynan
[1] Y. Suzuki,et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[2] N. Asai,et al. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. , 1996, Human molecular genetics.
[3] D. Baltimore,et al. Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides , 1993, Nature.
[4] R. Adar,et al. The Transmembrane Mutation G380R in Fibroblast Growth Factor Receptor 3 Uncouples Ligand-Mediated Receptor Activation from Down-Regulation , 2000, Molecular and Cellular Biology.
[5] J. Heath,et al. Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand. , 1998, Human molecular genetics.
[6] T. Gallardo,et al. Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. , 1996, The Journal of investigative dermatology.
[7] E. Zackai,et al. De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome. , 1999, American journal of human genetics.
[8] L. Cantley,et al. Vascular Dysmorphogenesis Caused by an Activating Mutation in the Receptor Tyrosine Kinase TIE2 , 1996, Cell.
[9] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[10] D. Donoghue,et al. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.
[11] Y. Yazaki,et al. Two aberrant splicings caused by mutations in the insulin receptor gene in cultured lymphocytes from a patient with Rabson-Mendenhall's syndrome. , 1998, The Journal of clinical investigation.
[12] Masahide Takahashi,et al. Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? , 1999 .
[13] Tony Pawson,et al. Protein modules and signalling networks , 1995, Nature.
[14] S. Hirota,et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.
[15] L. Mulligan,et al. Mutations of the RET proto‐oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease , 1997, Human mutation.
[16] F. Endo,et al. Congenital insensitivity to pain with anhidrosis: novel mutations in the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve growth factor. , 1999, American journal of human genetics.
[17] K. Walsh. The Protein Kinase Family , 1987 .
[18] D. Ornitz,et al. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.
[19] D. Donoghue,et al. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.
[20] M. Barbacid. The Trk family of neurotrophin receptors. , 1994, Journal of neurobiology.
[21] C. Deng,et al. Fibroblast growth factor receptors (FGFRs) and their roles in limb development , 1999, Cell and Tissue Research.
[22] Charis Eng,et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.
[23] T. Hunter,et al. The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. , 1998, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[24] M. Borrello,et al. Loss of function effect of RET mutations causing Hirschsprung disease , 1995, Nature Genetics.
[25] A. Munnich,et al. Ret in human development and oncogenesis , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.
[26] C. Birchmeier,et al. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. , 1998, Trends in cell biology.
[27] P. Choyke,et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.
[28] R. Stephens,et al. Neurotrophin signal transduction by the Trk receptor. , 1994, Journal of neurobiology.
[29] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[30] D. Donoghue,et al. FGFR activation in skeletal disorders: too much of a good thing. , 1997, Trends in genetics : TIG.
[31] B. Mroczkowski,et al. Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis. , 1999, Structure.
[32] C. Marshall,et al. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.
[33] G. Yancopoulos,et al. Dominant mutations in ROR2, encoding an orphan receptor tyrosine kinase, cause brachydactyly type B , 2000, Nature Genetics.
[34] S. Hubbard,et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.
[35] J. Burn,et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. , 1995, American journal of human genetics.
[36] R. Ferrell,et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. , 1998, Human molecular genetics.
[37] S. Shoelson,et al. Structure of the IRS-1 PTB Domain Bound to the Juxtamembrane Region of the Insulin Receptor , 1996, Cell.
[38] C. R. Kahn,et al. Genetics of non-insulin-dependent (type-II) diabetes mellitus. , 1996, Annual review of medicine.
[39] J. Kuriyan,et al. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms , 1993, Cell.
[40] D. Donoghue,et al. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. , 1999, American journal of human genetics.
[41] R. Spritz,et al. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. , 1992, American journal of human genetics.
[42] W. Fantl,et al. Signalling by receptor tyrosine kinases. , 1993, Annual review of biochemistry.
[43] J. Bautista,et al. Congenital insensitivity to pain with anhidrosis , 1980, Muscle & nerve.
[44] H. Tonoki,et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis , 1996, Nature Genetics.
[45] A. Bridges,et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. , 1994, Science.
[46] Vittorio,et al. Molecular heterogeneity of RET loss of function in Hirschsprung's disease. , 1996, The EMBO journal.
[47] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[48] D. Chopin,et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.
[49] D. Johnson,et al. Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.
[50] Cori Bargmann,et al. Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.
[51] D. Baltimore,et al. Modular binding domains in signal transduction proteins , 1995, Cell.
[52] S. Hubbard. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.
[53] D. Sanders,et al. Human piebaldism: relationship between phenotype and site of kit gene mutation , 1995, The British journal of dermatology.
[54] A. Bardelli,et al. Novel mutation in the ATP‐binding site of the MET oncogene tyrosine kinase in a HPRCC family , 1999, International journal of cancer.
[55] Joseph Schlessinger,et al. Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism , 1996, Cell.
[56] T. Hunter,et al. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.
[57] T. Hunter,et al. Receptor protein-tyrosine kinases and their signal transduction pathways. , 1994, Annual review of cell biology.
[58] W. Marston Linehan,et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.
[59] G. D. Vita,et al. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines , 1998, Oncogene.
[60] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[61] Marius Sudol,et al. From Src Homology domains to other signaling modules: proposal of the `protein recognition code' , 1998, Oncogene.
[62] C. Eng. RET proto-oncogene in the development of human cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] M. Quon,et al. Insulin signalling: metabolic pathways and mechanisms for specificity. , 1999, Cellular signalling.
[64] C. Eng. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. , 1996, New England Journal of Medicine.
[65] A. N. Meyer,et al. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[66] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[67] M. Saarma,et al. GDNF Family Neurotrophic Factor Signaling: Four Masters, One Servant? , 1999, Molecular and Cellular Neuroscience.
[68] W. Gullick,et al. Neu receptor dimerization , 1989, Nature.
[69] A. Kazlauskas,et al. Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal , 1993, Cell.
[70] G. Kosztolányi. Leprechaunism / Donohue syndrome / insulin receptor gene mutations: a syndrome delineation story from clinicopathological description to molecular understanding , 1997, European Journal of Pediatrics.